scholarly journals Clinicopathologic and Survival Characteristics of patients with squamous cell carcinoma and adenocarcinoma of uterine cervix in Yazd, Iran

2020 ◽  
Vol 3 (2) ◽  
pp. 57-61
Author(s):  
Fariba Binesh ◽  
◽  
Sanaz Azadi ◽  
Ali Akhavan ◽  
Tahmine Hashemi Zade ◽  
...  
Keyword(s):  
Overall Survival ◽  
Squamous Cell ◽  
Cox Regression ◽  
Cell Cancer ◽  
Chi Square ◽  
Historical Cohort ◽  
Factors Affecting ◽  
Frequency Table ◽  
Kaplan Meier ◽  
Chi Square Test

Introduction: Though the incidence of cervical squamous cell cancer (SCC) has reduced during recent years, the amount of cervical adenocarcinoma (AC) has propagated. There is a controversy over whether prognosis is better in SCC or AC. Similar studies have not been conducted in Iran. Material and methods: This is a descriptive-analytic study that is based on historical cohort method. In this retrospective work, all cases of cancer patients were studied from 2004 to 2015 and the medical records of all women recognized with cervical SCC and AC treated in Shahid Sadoughi teaching hospital and Shahid Ramesanzadeh Radiotherapy Center were recovered. In these patients, the epidemiologic characteristics, survival and the factors affecting the survival were investigated. Statistical analysis included frequency table and Chi-Square test. Patient survival was assessed using Kaplan- Meier assessments, and multivariate analysis was done by the Cox regression mode. Results: This study was done on 158 patients identified with cervical carcinoma. Their mean age at the time of diagnosis was 53.3987±1.02150 years. According to histopathologic types, 132 of the patients were classified as SCC with mean age of 52.4840±1.10612 years; while 26 patients were identified as AC with mean age of 58.0385±2.49830 years. The overall survival was 96.338±4.434 months (95% confidence interval) and it was 100.459±4.342 and 54.475±5.334 months for SCC and AC respectively. In the early and advanced stages, overall survival of patients with SCC was different (p=0.001). It was true about the patients with AC (p=0.002). Conclusion: The results of the current study showed the prognosis is worse in patients with cervical AC than cervical SCC

scholarly journals MicroRNA-124 alone might represent an indicator signifying cholangiocarcinoma prognosis

2020 ◽  
Author(s):  
Ning Wang ◽  
Yanni Li ◽  
Yanfang Zheng ◽  
Huoming Chen ◽  
Xiaolong Wen ◽  
...  
Keyword(s):  
Overall Survival ◽  
Cox Regression ◽  
Prognostic Biomarker ◽  
Prognostic Indicator ◽  
Rank Test ◽  
Chi Square ◽  
Log Rank Test ◽  
Kaplan Meier ◽  
Chi Square Test ◽  
Polymerase Chain

Abstract Background: Previous studies have demonstrated that microRNAs (miRNAs) played a crucial role in various diseases, including cancers. The aim of the study was to evaluate the clinical significance of miR-124 in patients with cholangiocarcinoma (CCA).Methods: The expression pattern of miR-124 was detected in CCA tissues using quantitative reserve transcription polymerase chain reaction (qRT-PCR). The correlation of miR-124 expression with clinicopathological features and overall survival of patients were explored using chi-square test, Kaplan-Meier methods and Cox regression analyses.Results: The miR-124 expression level was strong down-regulated in CCA tissues compared with normal para-cancerous tissues (P<0.001). Moreover, aberrant miR-124 expression was significantly associated with differentiation (P=0.045) and lymph node metastasis (P=0.040). In addition, Kaplan-Meier method and log-rank test revealed that patients with low miR-124 expression has a poorer overall survival compared with those with high miR-124 expression (P=0.002). Furthermore, multivariate analysis confirmed that miR-124 expression (P=0.006; HR=2.006; 95%CI: 1.224-3.289) was an independent prognostic indicator in CCA.Conclusions: Collectively, our results defined miR-124 expression plays important roles in CCA patients. MiR-124 expression might used as a valuable prognostic biomarker for patients with CCA.

scholarly journals The relationship between RECK Gene Polymorphisms and the prognosis of cholangiocarcinoma

2020 ◽  
Author(s):  
Ning Wang ◽  
Yanni Li ◽  
Yanfang Zheng ◽  
Huoming Chen ◽  
Xiaolong Wen ◽  
...  
Keyword(s):  
Overall Survival ◽  
Survival Rate ◽  
Cox Regression ◽  
Univariate Analysis ◽  
Overall Survival Rate ◽  
Chi Square ◽  
Cox Regression Analysis ◽  
Kaplan Meier ◽  
Chi Square Test ◽  
The Relationship

Abstract Background The study was designed to examine the reversion inducing cysteine rich protein with Kazal motifs (RECK) levels in patients with cholangiocarcinoma (CCA) and assess its role in CCA prognosis. Methods Quantitative real-time PCR (qRT-PCR) was used to determine the expression of RECK mRNA in 127 pairs of CCA samples and controls. Chi-square test was conducted to analyze the effects of clinical features on RECK expression. Kaplan-Meier curves were plotted to determine the overall survival rate of CCA patients with different RECK expression. The prognostic biomarkers for CCA patients were identified using the Cox regression analysis. Results Significantly down-regulated expression of RECK mRNA was determined in CCA tissues compared to noncancerous controls (P < 0.05). Chi-square test suggested reduced RECK expression was related with invasion depth (P = 0.026), differentiation (P = 0.025), lymphatic metastasis (P = 0.010) and TNM stage (P = 0.015). However, age, sex, tumor size and family history had no significant links with RECK expression (all, P > 0.05). The survival curves showed that patients with low RECK expression had a shorter overall survival rate than those with high RECK expression. Both the univariate analysis (P = 0.000, HR = 5.290, 95%CI = 3.195–8.758) and multivariate analysis (P = 0.000, HR = 5.376, 95%CI = 2.231–8.946) demonstrated that RECK was an independent biomarker for predicting the outcomes of CCA patients. Conclusions Taken together, the expression of RECK was down-regulated in CCA and it might be an efficient biomarker for CCA patients.

Survival Outcomes for Induction vs Adjuvant Chemotherapy in Squamous Cell Carcinoma of the Maxillary Sinus

2018 ◽  
Vol 160 (4) ◽  
pp. 658-663 ◽  
Author(s):  
Phoebe Kuo ◽  
Sina J. Torabi ◽  
Dennis Kraus ◽  
Benjamin L. Judson
Keyword(s):  
Overall Survival ◽  
Adjuvant Chemotherapy ◽  
Maxillary Sinus ◽  
Induction Chemotherapy ◽  
Squamous Cell ◽  
Cox Regression ◽  
Rank Test ◽  
Controlled Clinical Trial ◽  
Log Rank Test ◽  
Kaplan Meier

Objective In advanced maxillary sinus cancers treated with surgery and radiotherapy, poor local control rates and the potential for organ preservation have prompted interest in the use of systemic therapy. Our objective was to present outcomes for induction compared to adjuvant chemotherapy in the maxillary sinus. Study Design Secondary database analysis. Setting National Cancer Database (NCDB). Subjects and Methods In total, 218 cases of squamous cell maxillary sinus cancer treated with surgery, radiation, and chemotherapy between 2004 and 2012 were identified from the NCDB and stratified into induction chemotherapy and adjuvant chemotherapy cohorts. Univariate Kaplan-Meier analyses were compared by log-rank test, and multivariate Cox regression was performed to evaluate overall survival when adjusting for other prognostic factors. Propensity score matching was also used for further comparison. Results Twenty-three patients received induction chemotherapy (10.6%) and 195 adjuvant chemotherapy (89.4%). The log-rank test comparing induction to adjuvant chemotherapy was not significant ( P = .076). In multivariate Cox regression when adjusting for age, sex, race, comorbidity, grade, insurance, and T/N stage, there was a significant mortality hazard ratio of 2.305 for adjuvant relative to induction chemotherapy (confidence interval, 1.076-4.937; P = .032). Conclusion Induction chemotherapy was associated with improved overall survival in comparison to adjuvant chemotherapy in a relatively small cohort of patients (in whom treatment choice cannot be characterized), suggesting that this question warrants further investigation in a controlled clinical trial before any recommendations are made.

CIP4 Expression is Associated With The Prognosis in Colorectal Cancer

2020 ◽  
Author(s):  
Keqian Zhang ◽  
Tianqi Mao ◽  
Zhicheng He ◽  
Xiaojiao Wu ◽  
Yu Peng ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cox Regression ◽  
Prognostic Significance ◽  
Lymphatic Invasion ◽  
Chi Square ◽  
Interacting Protein ◽  
Cox Regression Analysis ◽  
Kaplan Meier ◽  
Chi Square Test ◽  
Student’S T

Abstract Background: This study was conducted to detect the expression of Cdc42 interacting protein 4 (CIP4) in patients with colorectal cancer (CRC), and explore the role of CIP4 in prognosis of CRC patients.Methods: The expression of CIP4 mRNA was determined by quantitative real-time PCR (qRT-CPR) and compared by student’s t-test between groups. Relationships of clinical characteristics and CIP4 expression were analyzed by Chi-square test. Kaplan-Meier curves were used to estimate the overall survival of CRC patients. And Cox regression analysis was conducted to identify the prognostic biomarkers for CRC patients.Results: The qRT-PCR results showed that CRC tissues were detected with significantly high CIP4 mRNA expression compared with adjacent normal controls (P<0.0001). The overexpression of CIP4 in CRC tissues was influenced by distant metastasis (P=0.021), lymphatic invasion (P=0.012) and TNM stage (P=0.006). But, other clinical factors including age, gender, differentiation and tumor site were proved to have no obvious effects on CIP4 expression (all, P>0.05). The survival curves showed that patients with high CIP4 expression generally lived shorter than those with low CIP4 expression (P<0.001). In addition, the multivariate analysis revealed that differentiation (P=0.044, HR=1.631, 95%CI=1.013-2.626) and CIP4 expression (P=0.000, HR=5.283, 95%CI=3.138-8.893) were of great prognostic significance for CRC patients.Conclusion: Taken together, up-regulation of CIP4 in CRC tissues represented poor prognosis for patients.

scholarly journals Neutrophil to Lymphocyte Ratio as Prognostic Indicator for Patients with Esophageal Squamous Cell Cancer

2017 ◽  
Vol 32 (4) ◽  
pp. 409-414 ◽  
Author(s):  
Guo-Dong Gao ◽  
Bo Sun ◽  
Xian-Bin Wang ◽  
Shi-Meng Wang
Keyword(s):  
Overall Survival ◽  
Squamous Cell ◽  
Cox Regression ◽  
Cell Cancer ◽  
Prognostic Indicator ◽  
Neutrophil To Lymphocyte Ratio ◽  
Cox Regression Analysis ◽  
Lymphocyte Ratio ◽  
Leukocyte Counts ◽  
Clinical Records

Background This study aimed to evaluate the correlation between neutrophil to lymphocyte ratio (NLR) with overall survival (OS) of esophageal squamous cell carcinoma (ESCC) patients. Method Records of patients with diagnosed ESCC were reviewed. Leukocyte counts and patients' characteristics were extracted from their clinical records to calculate NLR. Correlation between NLR and baseline characteristics with overall survival (OS) was then analyzed using Cox regression. The patients were then separated into higher and lower NLR groups according to median NLR. OS was further compared between the 2 groups. Results A total of 1281 patients were included in the study. Cox regression analysis showed a significant correlation of NLR with OS of ESCC patients. The median pretreatment NLR was identified as 2.86. Higher NLR was associated with worse prognosis in terms of OS. Conclusions Pretreatment NLR is independently associated with OS of ESCC patients. Therefore, NLR may be used as a predictive indicator for pretreatment evaluation and adjustment of treatment regimen.

Effect of the revised AJCC staging (7th edition) on prognostic stratification in patients with surgically resected esophageal squamous cell carcinoma.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 4103-4103
Author(s):  
Gloria Terase Minella ◽  
James D. Luketich ◽  
Jon M. Davison ◽  
Dan Winger ◽  
Ryan M. Levy ◽  
...  
Keyword(s):  
Overall Survival ◽  
Squamous Cell ◽  
Cox Regression ◽  
Linear Trend ◽  
Tumor Grade ◽  
Discriminatory Ability ◽  
7Th Edition ◽  
Kaplan Meier ◽  
Chi Squared ◽  
Prognostic Stratification

4103 Background: Historically, the AJCC esophageal staging system separated patients into prognostic groups based on tumor, node, and metastasis (TNM) classifications. In 2010, the 7th edition (AJCC 7) significantly modified esophageal squamous cell cancer (ESCC) staging by separating ESCC from adenocarcinoma, incorporating tumor grade and location for node negative cancers, and stratifying by the number of involved regional nodes for node positive cancers. Our study aim was to determine whether AJCC 7 stage groupings provide improved survival prognostication compared to 6th edition (AJCC 6). Methods: We abstracted pathology and survival for 150 consecutive ESCC patients who underwent esophagectomy (1994-2012); 44 patients received induction therapy. AJCC 6 and AJCC 7 stages were assigned and overall survival analyzed from esophagectomy to death or most recent alive contact and censored at 60 months. Discriminatory ability and homogeneity within subgroups was assessed with Kaplan-Meier curves and monotonicity comparisons were evaluated with linear trend chi-squared tests. Overall survival was compared using Cox regression and Akaike Information Criterion (AIC) used to assess model fit. Results: Compared to AJCC 6, AJCC 7 upstaged 32 patients from IIa to IIb and 1 patient from IIb to IIIa and downstaged 3 patients from stage IIa to Ib. AJCC 7 subclassified 42 AJCC 6 stage III patients (17 IIIa, 10 IIIb and 15 IIIC). Median overall survival was 19 months. Kaplan-Meier log-rank statistic indicated stronger differentiation in AJCC 7 (19.8 vs 29.7). Cox regression likelihood (19.5 vs 26.1), AIC (618.1 vs 611.6), and linear trend chi-squared at 24- (17.5 vs 24.3) and 60-months (13.3 vs 17.3), were all superior for AJCC 7 stage groupings (AJCC 6 vs AJCC 7, respectively). Conclusions: AJCC 7 stage groupings demonstrate superior homogeneity, discriminatory ability and monotonicity compared to AJCC 6. Incorporating the extent of nodal disease, tumor location and tumor grade into the revised AJCC 7 stage classification improves prognostic stratification of surgically resected ESCC patients, including patients who received induction therapy.

Lung cancer: Significance of place of diagnosis.

2018 ◽  
Vol 36 (34_suppl) ◽  
pp. 60-60
Author(s):  
Rohit Bishnoi ◽  
Chintan Shah ◽  
Jacobo Hincapie Echeverri ◽  
Katherine Robinson ◽  
Yu Wang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Emergency Department ◽  
Cox Regression ◽  
Health Care Cost ◽  
Small Cell ◽  
Cost Of Care ◽  
Chi Square ◽  
Kaplan Meier ◽  
Therapy Cost ◽  
Chi Square Test

60 Background: Patients who are diagnosed with lung cancer through emergency department tend to do poorly. We conducted a retrospective study to examine the effect of place of diagnosis on various cancer outcomes including survival, health care cost, and end-of-life (EOL) care. Methods: Patients who died from lung cancer between January 2015 and July 2017 were reviewed. Initial place of diagnosis was determined (Emergency Department/Urgent clinic (ED/UC) or Outpatient). Descriptive statistics, exact Pearson chi-square test, Kaplan-Meier method, and multivariable Cox regression model were used to compare the two groups. Results: 227 patients were included in the analysis. Median age at diagnosis was 65 years. 52% were male; 85% were white. 57% of patients were diagnosed through ED/UC, whereas 43% were diagnosed as part of an outpatient workup. Age, gender, race, and histology (small cell vs. non-small cell) did not vary significantly between the two groups. Rates of palliative care intervention and advance directives were similar. Patients diagnosed through ED/UC were more likely to be metastatic, have symptoms, and not receive any cancer directed therapy. Cost of care was similar between the two groups. Median survival in those who presented to ED/UC was significantly shorter (2.5 vs. 6.5 mo; p<0.001) with a hazard ratio of 1.7 (95% CI:1.3-2.3), even after adjusting for potential confounding factors (age, metastasis, insurance, smoking, treatment). Conclusions: Patients diagnosed with lung cancer through the ED/UC have worse outcomes than those diagnosed as an outpatient. Despite similar cost of care, survival outcomes are worse. This variable remains significant despite controlling for confounders in multivariate analysis.[Table: see text]

A Comparison Of Acute Myelogenous Leukemia Induction Therapies: High Dose Daunorubicin Vs Idarubicin

Blood ◽  
2013 ◽  
Vol 122 (21) ◽  
pp. 3951-3951
Author(s):  
Viet Q. Ho ◽  
Robert Cade ◽  
Gene A. Wetzstein ◽  
Van D Hoang ◽  
Alan List ◽  
...  
Keyword(s):  
Overall Survival ◽  
Stem Cell ◽  
Induction Chemotherapy ◽  
Cox Regression ◽  
Myelogenous Leukemia ◽  
High Dose ◽  
Consolidation Chemotherapy ◽  
Chi Square ◽  
Younger Patients ◽  
Chi Square Test

Abstract Background The optimal induction regimen for patients with acute myeloid leukemia (AML) remains unclear. Intensification of daunorubicin (DNR) dose during induction chemotherapy (90 mg/m2) in younger patients with AML has yielded improved complete remission (CR) rates and overall survival (OS) compared to 45 mg/m2. To date, daunorubicin 90 mg/m2 has not been compared to idarubicin for induction in younger patients. Herein, we compare induction outcomes using cytarabine plus either IDA or DNR 90 mg/m2 as induction chemotherapy in patients less than 65 years of age. Methods This is a single institution case controlled retrospective study evaluating patients aged 18 to 65 years who received induction chemotherapy for AML with either cytarabine 100 mg/m2 x 7 days and DNR 90 mg/m2 x 3 days or cytarabine 200 mg/m2 x 7 days and IDA 12 mg/m2 x 3 days at Moffitt Cancer Center (MCC). Patients who achieved CR were offered consolidation chemotherapy and/or allogeneic transplant as per standard guidelines. Clinical endpoints that were measured and compared include CR, OS and leukemia free survival (LFS). Patients were censored at time of transplant. Categorical variables were compared using Chi square test, and t- test for continuous variables. Cox regression was used for multivariate analysis. Remission rate were compared using Chi square test. Kaplan-Meier estimates were used for OS and LFS and Log Rank test was used to compare groups. All analyses were conducted using SPSS version 21. Results Between January 2005 and April 2013, 175 patients<= 65 years with newly diagnosed AML were included; 84 patients received induction chemotherapy at MCC with high dose DNR and 91 patients received IDA as described above. Baseline characteristics were similar between the two groups (Table 1). The median duration of follow up was 25.9 months. CR rates were similar between the DNR and IDA (74% vs 76%, p = 0.95). Rates of CR after first induction were also similar (61% vs 62%, p = 0.33). The median LFS was 10.2 months with DNR compared to 6.4 months with IDA (p=0.476) (Figure 1). Median OS was not reached in the DNR arm compared to the 18.4 months in the IDA arm (p=0.107) (Figure 2). No significant differences were observed in the number of patients receiving consolidation chemotherapy (70% vs 66%, p = 0.54) or allogeneic stem cell transplant (23% vs 25%, p = 0.68). There was no difference in 60 day mortality during induction chemotherapy (4.8% vs 5.5%, p = 1.00). In multivariate cox regression analysis anthracycline selection did not affect OS after adjusting for cytogenetic and molecular profile, CR, consolidation received or stem cell transplantation (hazard ratio, 1.25; 95% CI, 0.74-2.09; p = 0.402). Conclusion In younger adults with AML, induction chemotherapy with either IDA or DNR yielded similar rates of CR and LFS and OS. However, a trend towards increased overall survival was observed in the DNR cohort, adding further support to the use of high-dose daunorubicin as standard induction for AML. Disclosures: No relevant conflicts of interest to declare.

Converting i.v. nitroglycerin therapy to nitroglycerin ointment therapy: a comparison of two methods

1998 ◽  
Vol 7 (2) ◽  
pp. 123-130 ◽  
Author(s):  
GA Esposito ◽  
G Dunham ◽  
BB Granger ◽  
GE Tudor ◽  
CB Granger
Keyword(s):  
Clinical Outcomes ◽  
Cox Regression ◽  
Test Results ◽  
Nursing Time ◽  
Chi Square ◽  
End Points ◽  
Nitroglycerin Ointment ◽  
Kaplan Meier ◽  
Randomized Controlled Studies ◽  
Chi Square Test

BACKGROUND: Methods of converting treatment with i.v. nitroglycerin to treatment with nitroglycerin ointment 2% vary greatly and may affect the length of time patients remain in the ICU, nursing time, and possible recurrent angina. To date, no randomized, controlled studies have evaluated the methods used for conversion. OBJECTIVE: To evaluate two methods of conversion. METHODS: Two hundred patients receiving i.v. nitroglycerin at doses of 10 to 100 micrograms/min were randomized to two methods of conversion: (1) Apply nitroglycerin ointment and stop i.v. nitroglycerin 30 minutes later. (2) Decrease the dose of i.v. nitroglycerin by 10 micrograms/min every 15 minutes, apply one half the dose of nitroglycerin ointment when the original i.v. dose has been decreased by one half, and apply the full dose of the ointment when the i.v. nitroglycerin is stopped. The primary end point was the time patients remained in the ICU after the conversion. Secondary end points included time to hospital discharge, estimate of nursing time, and selected clinical end points. Kaplan-Meier and Cox regression analyses were used to evaluate time patients remained in the ICU and nursing time. Clinical outcomes were analyzed by using a chi-square test. RESULTS: Use of the first method reduced median time before transfer from the ICU by 23 minutes and median nursing time by 45 minutes. Analysis of all clinical outcomes showed no differences between the two methods. CONCLUSIONS: Use of the first method was associated with a reduction in the time patients remained in the ICU before transfer to another unit and savings in nursing time, but the two methods did not differ according to clinical outcomes.

Ifosfamide (IFO) and doxorubicin (DOX) dose-intensities seem related to overall survival in adult soft-tissue sarcoma (STS) patients

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 9581-9581
Author(s):  
G. F. Almeida ◽  
G. Castro ◽  
I. M. Snitcovsky ◽  
A. C. Bassani ◽  
M. E. Diz ◽  
...  
Keyword(s):  
Overall Survival ◽  
Tumor Size ◽  
Rank Test ◽  
Lower Grade ◽  
Chi Square ◽  
Outpatient Unit ◽  
Kaplan Meier ◽  
Chi Square Test ◽  
The Relationship ◽  
Palliative Setting

9581 Background: IFO/DOX dose intensities (DI) seem to impact on the outcome of STS. We explored retrospectively the relationship between DI and overall survival (OS) in STS. Methods: From Jan/00 to Jun/05, 70 untreated STS pts received IFO/DOX, 32 as neo/adjuvant and 38 in the palliative setting at our outpatient unit. Filgrastin was not mandatory. Median age 47 y (17–74 y), 44 male; mean tumor size 13.6 cm in the neo/adjuvant and 16.5 cm in the palliative group (p=0.202, t-test). Most frequent histologies: leiomyo (16 pts), synovial (13), malignant fibrous histiocytoma (8) and liposarcoma (8). 28 pts had lower/ 9 upper limb tumors, 9 retroperitoneal, 9 trunk, 6 mediastinal, 5 visceral and 4 head and neck. Kaplan-Meier survival curves were considered from diagnosis and compared by log-rank test. Results: For the 70 pts, the mean DI for IFO and DOX were 2.5±0.9 mg/m2/wk and 18.8±6.0 mg/m2/wk, respectively. There was no difference between neo/adjuvant and palliative IFO/DOX DI (p=0.314/p=0.247, respectively). With 19-mo median f-up, the median OS (mOS) was 43 mo in the neo/adjuvant group with an advantage for pts submitted to conservative surgeries (46.5 mo vs. 16.8 mo; HR 0.185, 95%CI 0.003–0.399, p=0.007) as well as in those diagnosed with tumors with less than 3 mitoses/10 HPF (48.3 mo vs. 18.8 mo; HR 0.272, 95%CI 0.058–0.871, p=0.031). No differences in mOS related to tumor size, margin status or primary sites were found. According to IFO DI, the mOS were 46.5 mo, not reached (NR), 14.5 mo and 43 mo for pts in the 1st and subsequent DI quartiles (chi-square test for trend, p=0.004). In the median f-up of 9.8 mo, pts in the palliative setting presented mOS 21.8 mo, superior in the lower grade subgroup (NR vs. 11.1 mo; HR 0.130, 95%CI 0.076–0.746, p=0.014) and in the STS not from extremities (40.9 mo vs. 10.8 mo; HR 2.152, 95%CI 0.959–5.137, p=0.063). According to IFO DI quartiles, we also found a direct correlation between mOS (11.3 mo, 19 mo, 45.1 mo, and NR) and DI (p=0.052), and similar trend was shown for DOX DI, with 11.3 mo, 10.3 mo, NR, and 40.9 mo mOS for the 1st, 2nd, 3rd and 4th quartiles (p=0.018). Conclusions: In these STS adult pts, we have found a relationship between IFO and DOX DI and OS. Further evaluations of more intensive chemotherapy schedules are warranted. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document